These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1693037)

  • 21. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
    Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
    Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of benign prostatic hypertrophy--its influence on sexual function].
    Kumamoto Y; Tsukamoto T; Aoki M; Sato Y; Umehara T; Yoshida O; Arai Y; Kubo T; Aoki H; Komatsu Y
    Hinyokika Kiyo; 1994 Aug; 40(8):745-59. PubMed ID: 7524291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
    Murakoshi M; Ikada R; Tagawa M; Nakayama T
    Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of sirolimus on sex hormone levels of male renal transplant recipients.
    Lee S; Coco M; Greenstein SM; Schechner RS; Tellis VA; Glicklich DG
    Clin Transplant; 2005 Apr; 19(2):162-7. PubMed ID: 15740550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Classification of patterns of nocturnal penile tumescence with continuous monitoring of penile rigidity: analysis of various factors affecting erection].
    Yasumoto R; Kawano M; Tsurusaki K; Yoneda Y; Ishii K; Khono T; Kumata N; Fukui J; Hayashi S; Tsujino T; Umeda M
    Hinyokika Kiyo; 1996 Apr; 42(4):285-8. PubMed ID: 8693961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical effects of chlormadinone acetate (CMA) on human benign prostatic hypertrophy--comparative study with hexestrol by a double blind trial (author's transl)].
    Shida K; Kondo A; Takai S; Sato S; Shimazaki J
    Horumon To Rinsho; 1979 Oct; 27(10):1159-72. PubMed ID: 92377
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
    Noguchi K; Takeda M; Hosaka M; Kubota Y
    Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
    Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
    Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
    Murakoshi M; Ikeda R; Fukui N; Nakayama T
    Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of nocturnal penile tumescence studies are abnormal in sexually functional diabetic men.
    Nofzinger EA; Reynolds CF; Jennings JR; Thase ME; Frank E; Yeager A; Kupfer DJ
    Arch Intern Med; 1992 Jan; 152(1):114-8. PubMed ID: 1728906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of oral administration of chlormadinone acetate on canine prostatic hypertrophy.
    Kawakami E; Tsutsui T; Shimizu M; Orima H; Makanae Y; Yajima K; Ogasa A
    J Vet Med Sci; 1993 Aug; 55(4):631-5. PubMed ID: 7691191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of levodopa on nocturnal penile tumescence: a preliminary study.
    Horita H; Sato Y; Adachi H; Suzuki N; Kato R; Hisasue S; Suzuki K; Tsukamoto T
    J Androl; 1998; 19(5):619-24. PubMed ID: 9796623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses].
    Carani C; Salvioli V; Scuteri A; Borelli A; Baldini A; Granata AR; Marrama P
    Arch Ital Urol Nefrol Androl; 1991 Sep; 63(3):341-5. PubMed ID: 1723220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
    Kogawa T; Yanagiya H; Takashima T; Higashino I; Kudo T; Suzuki T; Mikuni T; Kido K; Tsukui A; Yagihashi Y
    Hinyokika Kiyo; 1993 Mar; 39(3):281-7. PubMed ID: 7685143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
    Umeda K
    Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.